Friend or Foe? The Dual Role of Ferroptosis in Tumor Immunity and Immunotherapy
WIREs Mechanisms of Disease · 2026-03 · 18 (2-3)
DOI: 10.1002/wsbm.70009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Mechanisms of Disease, online erschienen am 17.06.2026. Verfasst von Fangyu Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Integrative Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Ferroptosis, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: Capital Health Research and Development of Special Fund.
Abstract (Originalsprache)
Ferroptosis, an iron‐dependent form of regulated cell death driven by lipid peroxidation, plays a context‐dependent dual role in tumor immunity and immunotherapy. On one hand, it can act as an immunogenic cell death mechanism, releasing damage‐associated molecular patterns that activate dendritic cells and promote T cell priming. On the other hand, ferroptosis may suppress antitumor immunity by triggering death or dysfunction in key immune cells, including T lymphocytes, dendritic cells, and macrophages. This review synthesizes current insights into the molecular determinants of ferroptosis sensitivity within the tumor microenvironment. It examines how immune cells can induce ferroptosis in cancer cells, and how tumors evolve resistance through upregulation of proteins like GPX4 and FSP1 or metabolic rewiring. The interplay between ferroptosis and immunity offers promising therapeutic avenues, such as combining ferroptosis inducers with immune checkpoint inhibitors or employing nanotechnology for targeted delivery. However, the net immunogenic outcome depends on temporal, cellular, and microenvironmental factors. Future strategies must aim to selectively induce immunogenic ferroptosis in tumors while preserving immune cell function, leveraging biomarkers and microenvironment modulation to optimize combination therapies in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Center for Integrative Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.
- Beijing University of Chinese Medicine, School of Clinical Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.
- Nutritional Science Department, The University of Texas at Austin, Austin, USA.
ORCID-Profile: Jing Luo
Förderung
- Capital Health Research and Development of Special Fund
Zitieren
APA
Liu, F., Halimulati, M., Luo, J., Jia, L., & Tao, Q. (2026). Friend or Foe? The Dual Role of Ferroptosis in Tumor Immunity and Immunotherapy. WIREs Mechanisms of Disease, 18(2-3). https://doi.org/10.1002/wsbm.70009
Vancouver
Liu F, Halimulati M, Luo J, Jia L, Tao Q. Friend or Foe? The Dual Role of Ferroptosis in Tumor Immunity and Immunotherapy. WIREs Mechanisms of Disease. 2026;18(2-3). doi:10.1002/wsbm.70009
BibTeX
@article{Liu2026,
author = {Liu, Fangyu and Halimulati, Mairepaiti and Luo, Jing and Jia, Liqun and Tao, Qingwen},
title = {Friend or Foe? The Dual Role of Ferroptosis in Tumor Immunity and Immunotherapy},
journal = {WIREs Mechanisms of Disease},
year = {2026},
volume = {18},
number = {2-3},
doi = {10.1002/wsbm.70009}
}
EUVIMED